Cyprotex has signed a strategic partnering deal with Cytocentrics that complements its existing technology and enables it to offer a full package of in vitro ion channel services. Cyprotex is well placed to benefit from regulatory changes in cardiac testing procedures for new pharmaceuticals. We maintain the view that Cyprotex has the ability to offer an expanding array of services to customers and to expand into new end markets. We remain upbeat and believe the group is capable of capitalising ....
